Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | CFTR | P13569 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | DUT | P33316 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25594852 | 0.88 | DUT (0.34) | DUT | |
| SCHEMBL15273722 | 0.84 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2POLBTDP1RAB9A | |
| SCHEMBL31206724 | 0.83 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2POLBTDP1RAB9A | |
| SCHEMBL2928812 | 0.83 | ALDH1A1 (0.43) | ALDH1A1SMN1; SMN2POLBTDP1RAB9A | |
| SCHEMBL26924584 | 0.81 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2POLBTDP1RAB9A | |
| SCHEMBL31206669 | 0.81 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2POLBTDP1HTT | |
| SCHEMBL30673263 | 0.80 | ALDH1A1 (0.41) | ALDH1A1SMN1; SMN2POLBTDP1RAB9A | |
| SCHEMBL25594850 | 0.78 | DUT (0.33) | DUT | |
| SCHEMBL25594871 | 0.78 | SMN1; SMN2 (0.52) | ALDH1A1SMN1; SMN2POLBTDP1RAB9A | |
| SCHEMBL29050070 | 0.78 | SMN1; SMN2 (0.49) | ALDH1A1SMN1; SMN2POLBTDP1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
| WO-2023086319-A1 | 6-HE TERO ARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | AJAX THERAPEUTICS, INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | ALDH1A1 3735/4885SMN1; SMN2 4718/4885POLB 1228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.